NCT00280410已完成2 期
Multicenter, Randomized, Open-Label Study Investigating The Superiority Of The Contrast Enhancement Effect Of E7337 On Tumor Like Lesion In The Dynamic CT Of The Liver Of Patients With Tumor Like Lesions In The Liver
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Eisai Inc.
- 入组人数
- 192
- 试验地点
- 14
- 主要终点
- Contrast enhancement effect on tumor-like lesions in the liver.
研究概览
简要总结
This is a multicenter, randomized, open-label study to investigate the superiority of the contrast enhancement effect of E7337 on tumor-like lesions in the Dynamic CT of the liver.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with a tumorous lesion in the liver observed in diagnostic imaging such as ultrasonography, etc., conducted between 1 and 35 days before administration of the investigational agent, who are scheduled to undergo a dynamic CT examination.
- •Patients between 20 and 80 years old at the time informed consent is obtained.
- •Patients weighing >= 55.6 and < 105.0 kg at the time consent is obtained and when the investigational agent is administered.
排除标准
- •Issues affecting the safety evaluation of the investigational agent:
- •Patients who will have undergone or are scheduled to undergo an examination using another contrast agent from 7 days before administration of the investigational agent up to the time follow-up examinations are performed on day 8 after administration.
- •Patients for whom there is a strong possibility that a follow-up period, which extends up until examinations are performed on day 8 after administration, would not be possible, (i.e., when it will not be possible to evaluate delayed adverse drug reactions).
- •Patients who have undergone or are scheduled to undergo surgical treatment or a therapy such as percutaneous ethanol injection therapy, percutaneous microwave coagulation therapy, radiofrequency ablation, or transcatheter arterial embolization, etc., from the time diagnostic imaging such as abdominal ultrasonography is performed up until follow-up examinations are conducted on day 8 after administration.
- •Patients who are unable to discontinue taking analgesics during the period from the morning when the investigational agent is administered until CT examinations are completed.
- •Patients who cannot stop taking biguanide antidiabetic drugs, such as metformin hydrochloride and buformin hydrochloride, for three days after study agent administration (including administration day).
- •Patients who are currently participating in another clinical study.
- •Patients who participated in another clinical study within the 6 months prior to providing informed consent to participate in this study.
- •General concerns relating to the safety of the subject:
- •Patients in the acute stage of illness with unstable symptoms, or patients in a life-threatening condition (when it is expected that emergency treatment may be required between the time of registration and the conclusion of the follow-up period, or when the patient is not expected to survive for 3 months following administration of the investigational agent, etc.)
- •Patients with a history of hypersensitivity to iodine or iodinated contrast agents.
- •Patients with serious thyroid disease (goiter, hyperthyroidism, etc.)
- •Patients with serious cardiopathy (New York Heart Association [NYHA] functional class IV heart failure, shock, cyanosis, peripheral circulatory insufficiency, ventricular tachycardia, ventricular fibrillation, or complete atrioventricular block)
- •Patients with serious hepatopathy [symptoms of liver failure (fulminant hepatitis) such as a disturbance of consciousness corresponding to grade 3 in the Criteria for Grading Adverse Drug Reactions of Medicinal Products.]
- •Patients with moderate serious nephropathy (acute kidney failure, chronic kidney failure, hydronephrosis, nephrotic syndrome, or uremia with serum creatinine levels of 2.0 mg/dL or more, corresponding to grade 2 or above in the Criteria for Grading Adverse Drug Reactions of Medicinal Products.)
- •Patients with bronchial asthma
- •Patients with acute pancreatitis
- •Patients with macroglobulinemia
- •Patients with multiple myeloma
- •Patients with tetany
- •Patients with pheochromocytoma or who are suspected of having pheochromocytoma
- •Pregnant and potentially pregnant women, and nursing mothers
- •Patients with a history of medicine hypersensitivity
- •Patients with serious myasthenia gravis
- •Patients judged by an investigator for any other reason to be ineligible for participation as a subject in this study.
结局指标
主要结局
Contrast enhancement effect on tumor-like lesions in the liver.
次要结局
- Contrast enhancement effect (amount of change in CT value) on the portal venous phase (portal vein, left and right lobes of the liver parenchyma). Contrast enhancement effect on the arterial phase (hepatic artery).
研究者
研究点 (14)
Loading locations...
相似试验
终止
不适用
Efficacy and Safety of Intravenous Treatment of TuberculosisTuberculosis, PulmonaryNCT04150367Yuria-Pharm166
Unknown
不适用
A Randomized Multicenter Study to Compare Two Types of Transplant in Adult Patients With Hematologic MalignanciesHematologic MalignanciesNCT02386332Instituto de Investigacion Sanitaria La Fe206
已完成
3 期
A Study of Rebif® Compared With Avonex® in the Treatment of Relapsing-remitting Multiple Sclerosis (MS)Multiple Sclerosis, Relapsing-RemittingNCT00292266EMD Serono677
已完成
2 期
Phase 2 Study to Evaluate the Preliminary Performance of the C13-URA Breath Test Kit in Dyspeptic SubjectsDyspeptic SubjectsNCT01677338Otsuka Pharmaceutical Co., Ltd.20
已完成
2 期
Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy.High Risk Proliferative Diabetic RetinopathyNCT01941329Association for Innovation and Biomedical Research on Light and Image94